PIPERAZINE TARTRATE

US Previously Marketed

First approved in 1954

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C4H10N2.C4H6O6
Molecular Weight	236.2224
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C1CNCCN1.O[C@H]([C@@H](O)C(O)=O)C(O)=O

InChI

InChIKey=VNFVKWMKVDOSKT-LREBCSMRSA-N

InChI=1S/C4H10N2.C4H6O6/c1-2-6-4-3-5-1;5-1(3(7)8)2(6)4(9)10/h5-6H,1-4H2;1-2,5-6H,(H,7,8)(H,9,10)/t;1-,2-/m.1/s1

HIDE SMILES / InChI

Molecular Formula	C4H6O6
Molecular Weight	150.0868
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C4H10N2
Molecular Weight	86.1356
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	substrate 1388 inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2C19 2057 P-gp 1741 BCRP 910 T-type Ca2+ channels 3	UGT2B10 131

Drug as perpetrator

Target	Modality	Activity
BCRP 985	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23658968/	likely
CYP1A2 2333	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/19589229/	likely
CYP2C19 2141	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/19589229/	likely
CYP2C9 2497	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/19589229/	likely
CYP2D6 2546	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/19589229/	likely
CYP3A4 2633	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/19589229/	likely
P-gp 1932	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/30626065/; https://pubmed.ncbi.nlm.nih.gov/23658968/	likely
T-type Ca2+ channels 3	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23395659/	likely

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
UGT2B10 131	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30049229/	likely
CYP2D6 1388	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15228152/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubmed.ncbi.nlm.nih.gov/29153425/; https://pubmed.ncbi.nlm.nih.gov/32828898/; https://pubmed.ncbi.nlm.nih.gov/22608963/; https://pubmed.ncbi.nlm.nih.gov/17027138/

Sourcing

Vendor/Aggregator	ID	URL
AAA Chemistry	AR-1C0729
ABI Chem	AC1L5Y7Y
Alfa Chemistry	133-36-8	https://www.alfa-chemistry.com/cas_133-36-8.htm
Chemieliva Pharmaceutical Co., Ltd	PBCM0219281
PubChem	258091	https://pubchem.ncbi.nlm.nih.gov/compound/258091
PubChem	76972105	https://pubchem.ncbi.nlm.nih.gov/compound/76972105

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:34:09 GMT 2025` Edited by `admin` on `Mon Mar 31 17:34:09 GMT 2025`
Record UNII	SM51XZC901
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NOXIUROTAN

Preferred Name

English

PIPERAZINE TARTRATE

Systematic Name

English

PIPERAZINE, (R-(R*,R*))-2,3-DIHYDROXYBUTANEDIOATE

Common Name

English

PIPERAZINE TARTRATE [MI]

Common Name

English

NSC-86780

Code

English

PIPERATE

Brand Name

English

PIPERAZINE, (2R,3R)-2,3-DIHYDROXYBUTANEDIOATE

Systematic Name

English

Piperazine tartrate [WHO-DD]

Common Name

English

Code System Code Type Description

FDA UNII

SM51XZC901